The combination of endocrine therapy and metronomic chemotherapy with vinorelbine could therefore be of interest for HR + /HER2− (Hormone receptor positive, human epidermal growth factor receptor 2 negative) breast cancers in a metastatic hormone-resistance setting. Here, ERBB2 is linked to breast carcinoma.